Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections

BACKGROUND: Dalbavancin (DAL) is a long-acting lipoglycopeptide with activity against Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). This study investigates DAL as sequential therapy in S. aureus bloodstream infections (BSIs). METHODS: We conducted a retrospective cohort st...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina, Kyle C, Lunowa, Cali, Lebin, Madelyn, Segerstrom Nunez, Andrea, Azimi, Sara F, Krsak, Martin, Mueller, Scott W, Miller, Matthew A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314917/
https://www.ncbi.nlm.nih.gov/pubmed/35899276
http://dx.doi.org/10.1093/ofid/ofac335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314917/
https://www.ncbi.nlm.nih.gov/pubmed/35899276
http://dx.doi.org/10.1093/ofid/ofac335

Ejemplares similares